Evidence map›Paper›PMID 40655539›Full record

ArticleFrontiers in aging2025

Possibility of screening for mild cognitive impairment via an eye tracking-based cognitive scale.

Naoki Kodama, Sou Takahashi, Masazumi Tsuji, Yuji Kawase, Satoshi Naruse, Katsuya Urakami

Abstract read
In one paragraph

Article in Frontiers in aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Naoki KodamaDepartment of Radiological Technology, Faculty of Medical Technology, Niigata University of Health and Welfare, Niigata, Japan.
Sou TakahashiDepartment of Radiological Technology, Faculty of Medical Technology, Niigata University of Health and Welfare, Niigata, Japan.
Masazumi TsujiTsuji Internal Medicine, Cardiology, and Dentistry Clinic, Tokyo, Japan.
Yuji KawaseKawase Neurology Clinic, Sanjo, Japan.
Satoshi NaruseMidori Hospital, Niigata, Japan.
Katsuya UrakamiDepartment of Dementia Prevention, School of Health Science, Faculty of Medicine, Tottori University, Yonago, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The Montreal Cognitive Assessment (MoCA) is widely used as a screening test for mild cognitive impairment (MCI). However, the MoCA takes approximately 15 min to administer and evaluate by skilled examiners, such as medical professionals. This study assessed whether an eye tracking-based cognitive scale using virtual reality (VR) was accurate and efficient to screen for MCI. Methods: This study included 143 patients. The Virtual Reality-Based Cognitive Function Examination (VR-E) was used with all participants to evaluate their memory, judgment, spatial cognition, calculation, and language function. Results: Significant differences were observed in all cognitive domains of memory, judgment, spatial cognition, calculation, and language function between the Alzheimer's disease (AD), MCI, and older healthy control (HC) groups. The area under the curve value of the VR-E score for the HC and MCI groups was 0.857, and that for the AD and MCI groups was 0.870. The correlation coefficient between the MMSE and VR-E scores was 0.566 (p < 0.001), and that between the Japanese version of the MoCA (MoCA-J) and VR-E scores was 0.648 (p < 0.001), which indicated a moderate correlation in both comparisons. Conclusion: The VR-E had the same diagnostic performance results as the MoCA-J, thus the VR-E has potential for use in screening patients for MCI.

Indexed as

Alzheimer’s diseaseeye tracking-based cognitive scalemild cognitive impairmentscreeningvirtual reality

Identifiers

PMID40655539
PMCPMC12246754

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.